Ritedose’s 2025 Year-In-Review highlights a year of growth, innovation, and purpose-driven impact, advancing patient access through expanded generics, operational excellence, and community investment.
A Year of Momentum: Celebrating Ritedose’s Successes
2025 marked Ritedose’s 30th anniversary and was a year full of measurable growth, renewed innovation and a meaningful impact. As the demand for safe, reliable and scalable pharmaceutical manufacturing continues to rise, we have strengthened our position as a leader in Blow-Fill-Seal (BFS) technology. From adding three new generic drugs to our portfolio to strategic investments in capacity and talent, 2025 showcased what’s possible when a company remains steadfast in the company’s commitment to the patient being at the heart of service. Here’s a look back at the milestones that defined an exceptional year.
Advancing Patient Access Through Generics Portfolio
One of the most significant accomplishments of the past year was the expansion of Ritedose Pharmaceuticals, the generics arm of Ritedose, whose portfolio grew through expanding our manufacturing of three generic drugs. Albuterol Sulfate Inhalation Solution (0.5%, 2.5 mg/0.5mL), Formoterol Fumarate Inhalation Solution (20 mcg/2 mL), and Tobramycin Inhalation Solution all significantly elevate patient care through expanded access to high-quality, unit-dose respiratory medications.
With these additions, Ritedose is now the largest nebulized portfolio in the United States, which solidifies its position as a leader in the industry. This is more than a milestone for us – it is a meaningful contribution to meeting growing patient needs and market demands. Respiratory diseases continue to rise with continued under-diagnosis and under-management of care. Ensuring consistent access to trusted medications is one way we fulfill our mission to “help patients get the medications they need to live their best lives.” It’s how we reinforce our commitment to doing right the first time, every time.
Operational Excellence and Capacity Expansion
Meeting rising customer demand requires precision, performance and capacity growth. These advancements went beyond upgrades; they were strategic investments designed to strengthen performance, efficiency, and long-term sustainability for the corporation.
- Seventh Syntegon Packaging Line: The addition of a seventh Syntegon packaging line doubled our capacity to package individually wrapped vial medications, supporting faster delivery to patients.
- Ritedose Performance Park: In June 2025, we celebrated the grand opening of the new distribution and logistics facility, which improves supply movement from manufacturing to market.
- cGMP Lab Expansion: A $17M investment in expanding our cGMP laboratory provides additional resources that positions Ritedose as a full-service manufacturing facility with our own testing services. With capabilities now exceeding 2.6B+ units per year, the investment significantly increases capacity by over 40%.
Working for the Greater Good
In The Community We Call Home
Our growth is powered by the people who make it possible. Over the past year, we have strengthened our commitment to workforce and community development through meaningful partnerships, outreach initiatives, and programs that support college, career, and professional growth.
Our 1000 Hours of Purpose initiative with the United Way of the Midlands launched in February 2025. Through it, we pledged to donate 1,000 hours of employee time to support various local organizations addressing basic human needs like hunger and housing. Employees receive monthly opportunities for a full day of volunteering with local organizations in the Midlands community like Transitions Homeless Center and Harvest Hope Food Bank. We want our employees to experience a career full of growth, but more importantly, a life full of impact.
Building a New Generation of Innovators
We launched a new Pharmaceutical Manufacturing program, in partnership with Newberry College, which began in the summer of 2025. This collaboration allows our experts to teach classes, giving Newberry students real-world knowledge for future pharmaceutical careers, and it builds on our commitment to fostering the next generation of life sciences professionals.
For our current Ritedose employees, we partner with Midlands Technical College to provide classes that help them to further develop skills and advance their careers while still maintaining their chosen path at Ritedose.
In previous years, we have forged similar initiatives. In 2024, Ritedose partnered with inSpring and Benedict College to develop RISE, a workforce initiative offering graduating international students a pathway to experience and careers.
Always Patient-Inspired and Purpose-Driven
And last but not at all least, we are donating one million doses of our products to the national charitable medication distributor, Dispensary of Hope, to provide respiratory medications to low-income and chronically ill patients nationwide.
Looking Ahead
The accomplishments of this past year are a testament to the dedication of the Ritedose team, and the trust placed in the company by its partners and customers. As the pharmaceutical landscape continues to evolve, the road ahead holds remarkable opportunity. We are prepared to build on our momentum, pursuing new innovations and continuing to deliver quality and reliability that define leadership in the industry.
